Showing 5771-5780 of 8887 results for "".
- Sirnaomics' STP705 Shows Promise in Adults with Cutaneous Squamous Cell Carcinoma In Situhttps://practicaldermatology.com/news/sirnaomics-stp705-shows-promise-in-adults-with-cutaneous-squamous-cell-carcinoma-in-situ/2461469/Sirnaomics' STP705 shows promise for the treatment of Cutaneous Squamous Cell Carcinoma In Situ (isSCC), according to interim results of part-one of an ongoing Phase IIb clinical trial. The majority (78%) of 32 patients with STP705 treatment achieved histologica
- Immunomic Therapeutics Receives FDA Fast Track Designation for pDNA Vaccine for Skin Cancerhttps://practicaldermatology.com/news/immunomic-therapeutics-receives-fda-fast-track-designation-for-pdna-vaccine-for-skin-cancer/2461468/Vaccine exclusively delivered with the PharmaJet Stratis® Needle-free Injection System
- Endo Removes Qwo from Market Due to Concerns About Injection Site Bruising, Skin Discolorationhttps://practicaldermatology.com/news/endo-removes-qwo-from-market-due-to-concerns-about-injection-site-bruising-skin-discoloration/2461467/Endo International plc is ceasing the production and sale of Endo Aesthetics' Qwo (collagenase clostridium histolyticum-aaes) in light of market concerns about the extent and variability of bruising following initial treatment as well as the potential for prolonged skin discoloratio
- Rocatinlimab Shows Promise in ADhttps://practicaldermatology.com/news/rocatinlimab-shows-promise-in-ad/2461465/Rocatinlimab—a novel, patient-tailored monoclonal antibody therapy—showed promising results in atopic dermatitis patients both while taking the drug and up to 20 weeks after the therapy was stopped, Mount Sinai researchers reported in
- UCB's Bimekizumab Performs Well in Hidradenitis Suppurativahttps://practicaldermatology.com/news/ucbs-bimekizumab-performs-well-in-hidradenitis-suppurativa/2461464/UCB’s bimekizumab may be a promising treatment approach in adults with moderate to severe hidradenitis suppurativa, according to topline results from two Phase 3 studies, BE HEARD I and BE HEARD II. The positive results from these two studies will form the basis of global reg
- UCB’s Bimekizumab Performs Well in PsA Studieshttps://practicaldermatology.com/news/ucbs-bimekizumab-performs-well-in-psa-studies/2461460/Two new studies highlight the efficacy and safety of bimekizumab in the treatment of adults with active psoriatic arthritis who were biologic-naïve and/or tumor necrosis factor inhibitor inadequate responders (TNFi-IR). The 24-week results from the Phase 3 BE OPTIMAL study and 16-w
- American Hair Research Society to Host Hybrid Alopecia Areata Summit 12/10-11https://practicaldermatology.com/news/american-hair-research-society-to-host-hybrid-alopecia-areata-summit-1210-11/2461459/The Alopecia Areata Summit “New Pathways, New Treatments” organized by the American Hair Research Society will be held December 10-11 at the New York Academy of Medicine, 1216 5th Ave., New York, NY. The meeting is being co-Chaired by Angela M. Christiano, PhD, Columbia Univ
- Arcutis Enrolls First Patient in Phase 1b Alopecia Areata Study of ARQ-255https://practicaldermatology.com/news/arcutis-enrolls-first-patient-in-phase-1b-alopecia-areata-study-of-arq-255/2461458/The first subject has been enrolled in a Phase 1b study evaluating Arcutis’ ARQ-255, a topical suspension of ivarmactinib, a potent and specific janus kinase 1 (JAK1) inhibitor, for the treatment of alopecia areata. ARQ-255 has been specifically formulated with Arcutis’
- Study: Eating Grapes May Protect Skin from UV Damagehttps://practicaldermatology.com/news/study-eating-grapes-may-protect-skin-from-uv-damage/2461452/Consuming grapes can protect against ultraviolet (UV) damage to the skin, according to a new study in Antioxidants. Folks showed increased resistance to sunburn after consuming 2 ¼ cups of grapes every day
- Almirall Appoints Mercedes Diz as VP, Corporate Strategyhttps://practicaldermatology.com/news/almirall-appoints-mercedes-diz-as-vp-corporate-strategy/2461449/Almirall named Mercedes Diz as its VP Corporate Strategy. Diz will also join Almirall's Management Board of Directors, effective December 1. Diz joined Almirall in 2002 and, since 2021, has held the position of Senior Director of Corporate Str